Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Sponsor
Eva Prescott
Study ID
NCT02602600
Phase
PHASE4
Status
Completed

Conditions

  • Microvascular Angina

Eligibility Criteria

Sex
FEMALE
Age
40 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    * Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks. * Weight maintenance diet for 2 weeks

Study Details

The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.

Key Dates

Start date
Nov 19, 2015
Status verified
Jul 2018
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.

Primary Outcome Measure

Change from baseline in Coronary Flow Reserve [ Time Frame: Assessed at baseline, week 4 and week 18 ]

Related Studies